Table 1 Patient characteristics

From: Clinical aspects of a phase I trial of 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent

Characteristic

No. of patients

Total patients

63

Gender

 Male

21

 Female

42

Age (years)

 Median

55

 Range

24–75

WHO performance status

 0

13

 1

22

 2

28

Tumour primary site

 Colon/rectum

20

 Ovary

11

 Melanoma

6

 Lung

5

 Breast

3

 Cervix

3

 Unknown primary

3

 Pancreas

2

 Oesophagus

2

 Kidney

2

 Soft-tissue sarcoma

2

 Other

4

Previous treatment

 Chemotherapy

55

 Radiotherapy

25

 Biotherapy/hormones

11

 None

1

Back to article page